Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.1338
-0.0074 (-5.24%)
At close: Apr 28, 2026, 4:00 PM EDT
0.1389
+0.0051 (3.81%)
After-hours: Apr 28, 2026, 7:12 PM EDT
Virax Biolabs Group Revenue
Virax Biolabs Group had revenue of $1.61K in the half year ending September 30, 2025, a decrease of -97.90%. This brings the company's revenue in the last twelve months to $2.99K, down -96.48% year-over-year. In the fiscal year ending March 31, 2025, Virax Biolabs Group had annual revenue of $6.33K, down -95.95%.
Revenue (ttm)
$2.99K
Revenue Growth
-96.48%
P/S Ratio
882.74
Revenue / Employee
$157
Employees
19
Market Cap
2.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.33K | -150.09K | -95.95% |
| Mar 31, 2024 | 156.42K | 147.86K | 1,727.11% |
| Mar 31, 2023 | 8.56K | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | 123.82K | 23.94K | 23.97% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 5.07M |
| GeoVax Labs | 2.49M |
| Scinai Immunotherapeutics | 1.31M |
| SciSparc | 1.31M |
| Azitra | 7.50K |
VRAX News
- 14 days ago - Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders - PRNewsWire
- 4 weeks ago - What's Behind The Jump In Virax Biolabs Stock? - Benzinga
- 4 weeks ago - Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation - PRNewsWire
- 5 months ago - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PRNewsWire
- 5 months ago - Virax Biolabs Group Limited Announces $5 Million Private Placement - PRNewsWire
- 5 months ago - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PRNewsWire
- 6 months ago - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes - PRNewsWire
- 8 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire